Woke_Mind_Virus
Posted - 3 days ago
$ABSI Doesn't make any money, burns a lot of money, is pretty much a start up, and RFK...
SenorFrog1
Posted - 3 days ago
$ABSI Might have to revisit this at 1.50
Shlobby
Posted - 4 days ago
$ABSI looks like spring setup if you are into that. Not my style but could be good trade $3 and up
amrelsherbiny
Posted - 5 days ago
@Bullbear1010101 $ABSI is a very good company with good management. Things take time and everything is possible
Bullbear1010101
Posted - 5 days ago
$ABSI over 4 a few days ago! looks like $10 is never again unless miracle. no position but sad
Bull0206
Posted - 1 week ago
$ABSI not understanding why this is dropping so hard, can any clarify who knows?
Kernmantel
Posted - 1 week ago
$ABSI Management should have warned that initial milestone payment for a new therapy is peanuts. It doesn't look like there is a growth strategy that doesn't include dilution in the next year or two. They need to reign in spending and focus on what will get the company the fastest to positive operational cash flows. Until then, Absci will be traded like any other pharma startup.
SenorFrog1
Posted - 1 week ago
$ABSI Looking ugly..I’ll wait for 2.50 before I get back in
IAmSpoli
Posted - 1 week ago
$ABSI all charts broken. Good luck to all holders
IAmSpoli
Posted - 1 week ago
$ABSI need to see $4.80 to validate the higher highs and higher low thesis
DrWodo
Posted - 1 week ago
$ABSI hope we wave goodbye to the 4 handle forever
TrendsetterTrading
Posted - 1 week ago
$ABSI Massive pennant pattern formation looking to breakout. Needs volume to carry through the $4.50 overhead resistance mark and this could be a runner
Stockboi_
Posted - 1 week ago
$ABSI earnings tomorrow by the way from what I understand
Stockboi_
Posted - 1 week ago
Only holds $PITA $ABSI $TPST
Dgiggler
Posted - 1 week ago
$ABSI pop at open looks likely, right before earnings in this market with this sentiment...
ChessGM
Posted - 2 weeks ago
$ABSI Heads up alert! Upcoming earnings on Tuesday, 11/12/2024 for $ABSI Neutral (5.0) Absci Corporation (NASDAQ: ABSI) is at a pivotal juncture as it prepares for its upcoming R&D Day and earnings report, which may significantly influence investor sentiment. The company is leveraging its generative AI capabilities in drug creation, recently collaborating with Twist Bioscience to design innovative therapeutic antibodies. This partnership could enhance Absci's competitive edge in the biotechnology sector, particularly in the rapidly evolving landscape of AI-driven drug development. Financially, Absci has been navigating a challenging market environment, reflected in its current P/E ratio, which stands at 25.5, indicating that investors are willing to pay a premium for its growth potential. However, concerns persist regarding its EPS growth, which has shown volatility, with analysts projecting a modest increase of 5% year-over-year. Revenue forecasts suggest a gradual uptick, with expected figures around $20 million for Q3 2024, reflecting a slight improvement compared to previous quarters, yet still trailing behind key industry peers, which exhibit more robust growth metrics. Looking ahead to the earnings report scheduled for November 12, 2024, market expectations are tempered. Analysts anticipate a mixed performance, with estimates suggesting a loss per share of $0.30, a figure that aligns with Absci’s ongoing investments in R&D and strategic alliances. Historically, Absci has faced challenges in meeting earnings expectations, which may weigh on its stock price if the upcoming results do not meet or exceed these consensus estimates. The upcoming conference call will be crucial for management to outline future growth strategies and address investor concerns, potentially impacting stock performance in the near term. Overall, while there is optimism surrounding Absci's innovative capabilities, the financial metrics and upcoming earnings performance suggest a cautious approach for investors. - Funds were net buyers of $ABSI during the previous reporting quarter. - Top 5 funds with large holdings in $ABSI: * Redmile Group LLC $25MM. New position. CGMFundRank: 73%, Fund Website: www.redmilegroup.com * ARK Investment Management LLC $17MM. New position. CGMFundRank: 61%, Fund Website: www.ark-invest.com * Casdin Capital LLC $3MM. New position. CGMFundRank: 59%, Fund Website: www.casdincapital.com * Boxer Capital LLC $2MM. New position. CGMFundRank: 72%, Fund Website: www.boxercap.com * Perceptive Advisors LLC $2MM. New position. CGMFundRank: 59%, Fund Website: www.perceptivelife.com - Last 10 days performance: -3% - Last 30 days performance: 5% - Last 90 days performance: 12% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal."
IAmSpoli
Posted - 2 weeks ago
$ABSI nearly 10 months of consolidation.